Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Linzess Filed for Add’l Indication of Chronic Constipation: Astellas
September 12, 2017
- Tumor Regression Seen in 93% of RCC Patients on Lenvima-Keytruda Combo
September 12, 2017
- Lenvima Stalls QOL Lowering in HCC Patients: Eisai
September 12, 2017
- Chugai Sues Nippon Kayaku over Herceptin Patent
September 11, 2017
- Eisai, Ono to Collaborate on Lenvima-Opdivo Combo in HCC
September 11, 2017
- Pres. Fredrickson Leaves AZ Japan Unit after 14 Months in Office
September 11, 2017
- Canalia, Japan’s 1st DPP-4/SGLT-2 Combo, Now Available
September 8, 2017
- Ethical Drug Sales Rise 0.4% in July: Crecon
September 8, 2017
- PI Starts in US for Daiichi Sankyo/Sanford Burnham’s TNAP Inhibitor
September 8, 2017
- Japan PIII for Atopic Dermatitis Drug Nemolizumab to Begin in October: Maruho
September 8, 2017
- Chugai to Expand Range of Drugs on Its Medication Optimization Support Application
September 8, 2017
- Sumitomo Dainippon Licenses Antiemetic to Maruishi in Japan, US
September 7, 2017
- Eisai, Merck to Expand Enrollment of Keytruda Combination Trials with Lenvima/Halaven
September 6, 2017
- Japanese Drug Majors Ratcheting Up Moves in CAR-T Space
September 6, 2017
- Spera Pharma Begins Business Capitalizing on “Takeda’s” Track Record, Aims to Become Japan’s No. 1 CDMO
September 6, 2017
- Takeda in CAR-T Therapy Pact with NCC/Yamaguchi Univ. Spin-Out
September 5, 2017
- Mitsubishi Tanabe to Beef Up Marketing System in Field of Autoimmune Diseases, Plans to Expand Expert Sales Force
September 5, 2017
- Aspen Completes Takeover of 4 Kyowa Kirin Brands
September 4, 2017
- BIKEN-Mitsubishi Tanabe Vaccine JV Now Up and Running
September 4, 2017
- Seikagaku, Ono Ink Definitive Deal on Osteoarthritis Treatment
September 4, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…